Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
215 studies found for:    "Hairy cell leukemia"
Show Display Options
Rank Status Study
1 Recruiting Therapy Optimisation for the Treatment of Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: Cladribine s.c. injection, HCL treatment
2 Terminated
Has Results
Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: BL22 (CAT-3888)
3 Active, not recruiting LMB-2 to Treat Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
4 Recruiting Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Interventions: Drug: Cladribine;   Drug: Rituximab
5 Completed Rituximab in Hairy Cell Leukemia: a Multicenter Retrospective Study
Condition: Hairy-cell Leukemia
Intervention: Other: Data collection
6 Recruiting Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Interventions: Drug: Pentostatin;   Drug: Rituximab;   Drug: Bendamustine
7 Completed A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: Roferon-A
8 Active, not recruiting BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: Vemurafenib
9 Recruiting Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
Conditions: Hairy Cell Leukemia;   Hairy Cell Leukemia Variant
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
10 Completed Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab
Condition: Hairy Cell Leukemia (HCL)
Intervention: Drug: 2CdA +/- Rituximab
11 Completed A Phase I, Multicenter Dose Escalation Study in Patients With Leukemia
Condition: Hairy Cell Leukemia
Intervention: Biological: CAT 8015 (Moxetumomab Pasudotox)
12 Completed BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia
Condition: Leukemia
Intervention: Drug: BL22
13 Completed Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia
Condition: Leukemia
Interventions: Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunohistochemistry staining method
14 Completed Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy
Condition: Leukemia
Intervention: Biological: rituximab
15 Completed Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia
Condition: Leukemia
Interventions: Drug: 2-chlorodeoxyadenosine (CDA) daily;   Drug: 2-chlorodeoxyadenosine weekly
16 Recruiting 2CDA With Rituximab in Hairy Cell Leukemia
Condition: Leukemia
Interventions: Drug: Cladribine;   Drug: Rituximab
17 Unknown  Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
Conditions: Leukemia;   Hairy Cell Leukemia;   HCL
Interventions: Drug: Immunotoxin therapy;   Drug: CAT-8015 Immunotoxin;   Procedure: Biological therapy
18 Active, not recruiting Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Condition: Leukemia, Hairy Cell
Interventions: Drug: moxetumomab pasudotox;   Drug: IV Bag Protectant for Moxetumomab pasudotox
19 Recruiting Clinical Research in Hairy Cell Leukemia:Surveillance and Documentation of Clinical Outcomes
Condition: Leukemia, Other
Intervention:
20 Unknown  Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease
Conditions: Hairy Cell Leukemia;   Splenic Marginal Zone Lymphoma
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.